Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. In addition to his role at Context, Martin is the Director of Philly BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.
Dr. Kim is Co-founder, Chief Scientific Officer, and Chair of the Scientific Advisory Board of Context Therapeutics. In addition, Felix currently serves as a Member of the Sidney Kimmel Cancer Center at Thomas Jefferson University, Assistant Professor at Drexel University, and Secretary/Treasurer of the Translational and Clinical Pharmacology division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He is an expert in the pharmacology and biology of Sigma1 in cancer and in Sigma1 drug discovery. He has produced novel technologies and small molecule compounds used by scientists around the world to elucidate the role of Sigma1 in disease. He holds a BS in Biochemistry & Cell Biology from the University of California at San Diego, a PhD in Biochemistry from the Université de Montpellier (France) for work performed at the Centre National de la Recherche Scientifique, and performed a post-doctoral fellowship in the Molecular Pharmacology & Chemistry Program at Memorial Sloan Kettering Cancer Center.
Dr. Erard Gilles is the Chief Medical Officer of Context Therapeutics. Erard is a career clinical oncology physician, research director and pharmaceutical research and development leader with extensive experience in clinical trial design and operations, regulatory submissions and tactical pharmaceutical development. Most recently, Dr. Gilles was founder and Chief Medical Officer of Invivis Pharmaceuticals which found and patented a biomarker predictive of anti-progestin activity and licenced it to Arno Therapeutics, a publicly traded biotech company focused on developing an anti-progestin for castration resistant prostate cancer (CRPC). Prior, Erard held roles of increasing responsibility at Johnson & Johnson, Genta, Inc, Aventis Pharmaceuticals, and Roche Pharmaceuticals. From 1994-2000, Erard was Head of R&D, Medical Affairs in Europe for Pharmacia. From 1987-1991, Erard was an Assistant Professor of Oncology at the Institut Gustave Roussy Cancer Center. He holds an M.D. from Paris V Necker Enfants Malades and a Dimplomate in Clinical Oncology from Institut Gustave Roussy. In addition, Erard holds multiple Masters degrees in Pharmacology, Biostatistics, and Business from University of Parix XI and ESSEC Business School.
Dr. Scott Dax is Head of Chemistry at Context Therapeutics. In addition to his role at Context, Scott is a Co-founder of CerSci Therapeutics and is a Project Manager at BioMotiv, an early stage venture capital fund. Previously, Scott served as Chief Technology Officer at Galleon Pharmaceuticals, a venture-backed startup focused on developing therapeutics to treat narcotic-induced respiratory depression and sleep apnea. Prior, Scott served as Analgesics Research Team Leader at Johnson & Johnson where he gained extensive experience in the Sigma1 field. Earlier in his career, Scott held positions of increasing responsibility at DuPont-Merck and Hoffmann-LaRoche. Scott is an inventor of over 100 issued patents and 100 publications and presentations in peer-reviewed journal and professional societies. He holds an M.S. and Ph.D. in Chemistry from the University of Michigan and completed his postdoctoral training at the University of Wisconsin.
Mr. John Vaillancourt is Head of Bioinformatics at Context Therapeutics. John is an experienced biologist and computer scientist – a unique skill set ideally suited to therapeutic biomarker discovery and validation. Previously, John was a Bioinformatician at Caprion Proteomics where focused on mass spectrometry datasets for target discovery and validation. Prior, John was a Bioinformatics Scientist for 19 years at Merck Frosst where he regularly interacted with senior management and worked on progress across a range of therapeutic areas and development stages. In 2009, John was awarded the Merck Award of Excellence for his work on a tool to streamline the selection of potential drug candidates. He holds an M.Sc. in Biochemistry and a B.Sc. both from Queen’s University.
Dr. Evan Dick is currently SVP of Discovery Medicine at Aclaris Therapeutics, a publicly-traded dermatology company, and a Partner at NeXeption, a therapeutic incubator. Previously, Evan was SVP of Chemistry at Ralexar Therapeutics, a venture-backed autoimmune startup. Prior, Evan served as SVP of R&D or BD at multiple successful venture-backed startups, including Ceptaris Therapeutics (acquired by Actelion), Ception (acquired by Cephalon), and Fulcrum Pharmaceuticals (acquired by Ception). Evan gained additional startup experience at Kereos, MedStrategy, and Cytotaxis. Prior, Evan was Head of Ophthalmology R&D at G.D. Searle & Company. Evan was also an Assistant Professor in the Departments of Ophthalmology and Pharmacology at the Washington University School of Medicine. He earned a B.S. from Cornell University and Ph.D. from SUNY Buffalo.
Dr. Ford-Hutchinson is currently a Board Member or Scientific Advisor to multiple startup companies and private foundations. Tony has over 30 years of experience in pharmaceuticals, including an extensive tenure at Merck & Co. At Merck Frosst, Canada, Tony led teams that developed Singulair®, Cox-2 inhibitors (Vioxx® and Arcoxia®), prostaglandin DP receptor antagonist (a component of Tredaptive®) and Cat K inhibitors (odanacatib) making the Merck Frosst Laboratories the most productive discovery unit of Merck. Subsequent career highlights at Merck relating to infectious disease include the development of HIV integrase inhibitor Isentress® and development & licensing of therapies to tackle drug-resistant bacterial infections. Tony's most recent responsibility at Merck as head of Vaccine R&D led to commercialization of 4 vaccines; Gardasil®, Zostavax®, Proquad® and Rotateq®. Tony is Chairman of the Board of Directors, MSD Wellcome Trust Hilleman Labs, Board of Trustees, and President, Merck Genome Research Institute.
Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. In addition to his role at Context, Martin is a Director of BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.
Dr. Martin Phillips is currently Co-Founder and CEO of Opsidio, a fibrosis-focused startup. In addition, Martin is also CEO of Tarnhelm Therapeutics, an Advisor to Integral Molecular, and on the Steering Committee of Mid-Atlantic BioAngels. Martin brings nearly 30 years of experience including a career in academic medicine, biotech and the pharmaceutical industry. Previously, Martin served as the Chief Medical Officer at two venture-backed startups: Morphotek (acquired by Eisai), an antibody discovery platform; and a Millendo Therapeutics, a rare disease drug discovery company. Prior, Martin was VP of Clinical R&D at Aventis Behring, an Assistant Professor of Medicine at Baylor College of Medicine, and an Associate Professor at University of Texas-Houston. He holds an M.D. from Wayne State University School of Medicine and a B.S. from the University of Michigan.
Dr. Sorensen is President and Chief Executive Officer and Board Director of Galera Therapeutics. Mel is a Medical Oncologist who has spent 7-8 years each in patient care (including his oncology fellowship at the Mayo Clinic), in academia (at the National Institutes of Health), in leadership positions in clinical development in the pharmaceutical industry (GlaxoSmithKline and Bayer), and as President & CEO of private venture-funded biotechs, including Ascenta Therapeutics and Galera Therapeutics. He also serves as Chairman of other biotech companies, including OncoFusion Therapeutics. At Ascenta, Mel raised approximately $100 million in private financing and venture debt and secured global and regional deals for its three programs. Operationally, in about five years, Ascenta advanced two unrelated preclinical programs into broad clinical testing, managed multiple clinical trials, and developed an R&D presence in China. Mel is an advisor to the Biomarkers Consortium of the National Institutes of Health.
Dr. Ulrich is currently a Senior Advisor to Frazier Healthcare Partners. In addition, Roger on the Board of Directors of Remedy Pharmaceuticals, Aminex, and is a Scientific Advisor to Mllendo Therapeutics. Previously, Roger was Chief Scientific Officer of Acerta Pharma (acquired by AstraZeneca) and Co-founder and Chief Development Officer of Calistoga Pharmaceuticals (acquired by Gilead). Prior to Calistoga, Roger was Senior Scientific Director with Merck Research Laboratories and Director of Drug Safety Evaluation at Abbott Laboratories. Earlier, Roger was a Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Roger has authored more than 120 publications and is a Fellow of the Academy of Toxicological Sciences. He holds a Ph.D. in Cellular and Molecular Biology from West Virginia University.
Dr. Jean-Pierre (“JP”) Bizzari currently is a member of the Board of Directors of Halozyme, Nordic Nanovector Onexeo, Transgene, and previously of Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals). JP has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Abraxane®, Irinotecan® (CPT-11). As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Prior to serving as an advisor to emerging biotechnology companies, JP served as EVP and Group Head of Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene (2008-2015). Previously, JP served as VP of Clinical Oncology Development at Sanofi-Aventis (2002-2008), VP of Clinical Oncology at joined Rhône-Poulenc Rorer (1993-2002), and Head of Oncology at Servier (1983-1993). He holds an M.D. specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.
Dr. Felix Kim is the Co-founder, Chief Scientific Officer, and Chair of Scientific Advisory Board of Context Therapeutics. In addition, Felix is currently an Assistant Professor in the Department of Pharmacology & Physiology at Drexel University College of Medicine and is Secretary/Treasurer of the Translational and Clinical Pharmacology division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Prior to receiving his faculty position at Drexel, Felix completed a Post-Doctoral Fellowship with Dr. Gavril Pasternak at the Memorial Sloan Kettering Cancer Center. Felix is a leading authority on Sigma1 biology, having authored some of the seminal works in the field. He holds a Ph.D. in Biochemistry from Universitè Montepellier (France) and a B.S. in Biology from University of California San Diego.
Dr. Knudsen is the Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University. Karen serves on a multitude of national scientific advisory boards and committees, including those for the National Institutes of Health (NIH), American Association for Cancer Research, the Endocrine Society, and the Prostate Cancer Foundation. She is the Editor-in-Chief of Molecular Cancer Research, a senior editor for Cancer Research, and is on the editorial boards of Molecular Cancer Therapeutics, Endocrine-Related Cancer, American Journal of Pathology, Molecular Endocrinology, and Oncogene. Karen has received numerous awards for her research, including the Ronald Ross Award for Excellence in hormone-dependent malignancies from the Pacific Rim Breast and Prostate Cancer Research Organization and the Richard E. Weitzman Laureate Award from the Endocrine Society. Karen’s research identifying tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and led to the development of several innovative biomarker-driven clinical trials. Karen received a BS in Biology from The George Washington University, a PhD in Molecular Biology from the University of California at San Diego, and performed a post-doctoral fellowship at the Ludwig Institute for Cancer Research.
Dr. Kruse is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. In 2016, Andrew’s group published in Nature the first crystal structure of Sigma1. His research focuses on the molecular basis of transmembrane signaling through pharmacology and structural biology. This work was recently described as a “landmark achievement for molecular pharmacology and drug discovery” (F1000Prime review by Bryan Roth, UNC Chapel Hill). Andrew has received multiple prestigious awards, including the Sloan Research Fellowship (2017), Forbes 30 under 30 (2016), and the NIH Director’s Early Independence Award (2015). He holds bachelor’s degrees in Biochemistry and Mathematics from the University of Minnesota and a PhD in Structural Biology from Stanford University.
Dr. Mostaghel is Associate Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Associate Professor of Medical Oncology Division at the University of Washington School of Medicine. Elahe is a genitourinary oncologist who has lead multiple translational research programs on the development of strategies to treat hormone refractory prostate cancer and is involved in clinical trials for all phases of prostate cancer therapy. She is a program leader in the Pacific Northwest Prostate Cancer Specialized Programs of Research Excellence (SPORE). She holds AB in Biology from Harvard University, a PhD in immunology and MD from Duke University, and performed her residency at the University of California at San Francisco and an oncology fellowship at the Fred Hutchinson Cancer Research Center.